Business Wire

NJ-RUNPOD

8.5.2024 15:08:27 CEST | Business Wire | Press release

Share
RunPod Raises $20M in Seed Funding Co-led by Intel Capital and Dell Technologies Capital

RunPod, the launchpad that empowers developers to deploy custom full-stack AI applications, today announced it raised $20M in Seed funding, co-led by Intel Capital and Dell Technologies Capital with participation from Julien Chaummond, Nat Friedman, and Adam Lewis. In conjunction with the financing, Mark Rostick, Vice President and Senior Managing Director at Intel Capital, will join RunPod’s board of directors.

RunPod is a globally distributed GPU cloud computing service for training, deploying, and scaling AI models. Using RunPod’s two core products, GPU Cloud and Serverless, developers can spin up an on-demand GPU instance in a few clicks and create autoscaling API endpoints for scaling inference on AI models in production.

“The ability to create and deploy AI applications at scale will be paramount to their adoption and utilization,” said Amjad Masad, RunPod investor. “The RunPod team has clearly prioritized the developer experience to create an elegant solution that enables individuals to rapidly develop custom AI apps or integrations while also paving the way for organizations to truly deliver on the promise of AI.”

RunPod makes it simple for developers to seamlessly run any GPU workload, allowing them to focus less on Machine Learning operations and more on building their applications. These capabilities have proven advantageous to developers and resulted in RunPod’s swift expansion with 10-fold revenue growth year over year.

“RunPod started as a playground for developers and innovators, a place where they went to do their research, develop and finetune their projects; now, it boasts a community of over 100K developers,” said Zhen Lu, co-founder and CEO of RunPod. “We’ve grown so quickly because RunPod strikes the perfect balance between providing developers with the freedom to launch whatever they want, while still having the necessary infrastructure and tools in place to assist in the customization, development, and deployment of differentiated products.”

The emergence of AI-specific workloads has given rise to increased computational demands. Once the go-to solution, out-of-the-box cloud infrastructure platforms are no longer cost-effective or fast enough to create custom-differentiated products. With RunPod, developers can reliably and simply develop, train, scale, and launch custom full-stack AI applications or integrations in the cloud on a global scale.

“RunPod is rapidly growing both its customer base and revenue by offering a broad, fast, and easy-to-use platform that meets the needs of developers and their model-based applications," said Mark Rostick, Vice President and Senior Managing Partner at Intel Capital. “I’ve watched RunPod’s momentum scale from a small startup offering individual developers an ecosystem to kickstart their research and development to a serverless offering that allows enterprise customers to scale their customized high-grade products and solutions.”

Rapid growth and developer adoption created the need to grow the team almost 10x in the past year, establishing itself as a leader pioneering GPU AI-powered transformation. The platform has recently launched the ability to deploy CPU compute instances, a huge milestone in creating a holistic cloud solution. This Seed funding will enable RunPod to enhance the day-to-day life of developers, form new partnerships and integrations for seamless user experiences, and offer new and existing customers the perfect foundation for developing custom AI models.

“As the enterprise deploys more AI applications into production, the key to their success is access to fast, reliable, and scalable infrastructure. This is what Zhen, Pardeep, and the team have built with the RunPod platform,” said Radhika Malik, Partner at Dell Technologies Capital. “They are committed to keeping the dev experience central to everything they do. That’s resulted in overwhelmingly positive sentiment from the community and impressive, sustained user growth.”

About RunPod:

RunPod is a globally distributed GPU cloud platform that empowers developers to deploy custom full-stack AI applications – simply, globally, and at scale. With RunPod’s key offerings, GPU Instances and Serverless GPUs, developers can develop, train and scale AI applications in one cloud within seconds. RunPod is committed to making cloud computing accessible and affordable without compromising features, usability, or experience. It strives to empower individuals and enterprises with cutting-edge technology, enabling them to unlock the potential of AI and cloud computing. To learn more about RunPod, visit https://www.runpod.io/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508053225/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye